2. Disease Areas
  3. Musculoskeletal Disease
  4. Muscle Disease

Muscle Disease

Muscle disease refers to a group of conditions that impair muscle function, broadly classified into acquired and inherited forms, with inherited types including genetic disorders like muscular dystrophy.

 

Muscle Disease (60):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P990051
    Delpacibart 2653183-66-3 98.06%
    Delpacibart is a humanized IgG1κ monoclonal antibody targeting the transferrin receptor TFRC. Delpacibart can be conjugated with the phosphorodiamidate morpholino oligonucleotide (PMO) Zotadirsen (HY-177972), which targets exon 44 of the dystrophin gene, to synthesize the antibody-oligonucleotide conjugate (AOC) Delpacibart zotadirsen (HY-177564). Delpacibart is suitable for use in Duchenne muscular dystrophy (DMD44) research.
    Delpacibart
  • HY-102020
    RG3039 1005504-62-0 99.30%
    RG3039 (PF-06687859) is an orally active, blood-brain barrier-permeable DcpS inhibitor with an IC50 of 4.2 nM against hDcpS. RG3039 inhibits the decapping activity of DcpS and maintains DcpS in a catalytically inactive conformation in the central nervous system and other tissues. RG3039 extends survival and improves function in spinal muscular atrophy mice. RG3039 is applicable to research related to spinal muscular atrophy.
    RG3039
  • HY-114367
    Delphinidin 3-rutinoside chloride 15674-58-5 98.83%
    Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes.
    Delphinidin 3-rutinoside chloride
  • HY-19699
    1-Naphthylacetamide 86-86-2
    1-Naphthylacetamide is an orally active nonsteroidal anti-inflammatory agent (NAIA) and also an indole-type auxin plant growth regulator. 1-Naphthylacetamide inhibits inflammatory response-related pathways and modulates plant hormone signaling, exhibiting anti-inflammatory, local anesthetic, antispasmodic, analgesic, and diuretic activities. 1-Naphthylacetamide promotes plant cell expansion, differentiation, and fruit enlargement. Additionally, 1-Naphthylacetamide induces central nervous system (CNS) depression in mice, characterized by reduced spontaneous activity, decreased irritability, decreased muscle tone, and attenuated ear-cuff reflex, ipsilateral flexor reflex, and corneal reflex[1][2].
    1-Naphthylacetamide
  • HY-N0340
    Scopolamine butylbromide 149-64-4 99.97%
    Scopolamine butylbromide (Hyoscine butylbromide) is an orally active anticholinergic agent and spasmolytic. Scopolamine butylbromide binds with high affinity to rat cardiac M2 (Ki 83 nmol/L), hM2 (Ki 233 nmol/L), rat intestinal M3 (Ki 290 nmol/L) and hM3 (Ki 643 nmol/L) muscarinic receptors. Scopolamine butylbromide exerts a dose-dependent antagonistic effect on Carbachol-induced gastrointestinal smooth muscle spasm. Scopolamine butylbromide can be used for the research of abdominal colic and pain associated with gastrointestinal spasm, functional abdominal pain, chronic gastropathy and gastric ulcer.
    Scopolamine butylbromide
  • HY-177971
    Braxlosiran
    Braxlosiran, one of the components of the AOC Delpacibart braxlosiran (HY-177566), is composed of a siRNA targeting DUX4 (dual homologous box protein) and SMCC linker (HY-42360). Abnormal expression of the DUX4 protein leads to changes in gene expression in muscle cells, and these changes are associated with the loss of muscle function in facioscapulohumeral muscular dystrophy (FSHD).
    Braxlosiran
  • HY-180944
    BE2012 667889-47-6 99.49%
    BE2012, SR8278 (HY-14415) derivative, is a potent and selective REV-ERBα/β Antagonist with EC50 values of 0.285 and 0.346 μM. BE2012 binds to the ligand-binding domain (LBD) of REV-ERB, preventing the receptor from recruiting co-inhibitory factors and thereby releasing the transcriptional repression on downstream target genes. BE2012 can upregulate the expression of myogenic transcription factors Myf5 and Myod, promoting muscle regeneration and repair in acute muscle injury micemodels.
    BE2012
  • HY-147262
    Etedesiran
    Etedesiran is a component of the AOC drug Delpacibart etedesiran (HY-177565), formed by the reaction of an siRNA that induces cleavage of mRNA encoding myotonic dystrophy protein kinase (MTPK or DMPK) with SMCC linker (HY-42360). Etedesiran carries a maleimide group at its terminus, which can react with cysteine or lysine and is used for the synthesis of AOC drugs. Etedesiran is applicable to research related to myotonic dystrophy type 1.
    Etedesiran
  • HY-77785
    2-Amino-5-chlorobenzophenone 719-59-5 99.98%
    2-Amino-5-chlorobenzophenone (5-Chloro-2-aminobenzophenone) is a chemical intermediate. Derivatives of 2-Amino-5-chlorobenzophenone serve as skeletal muscle relaxants. 2-Amino-5-chlorobenzophenone acts as a starting material for the synthesis of anti-biofilm 2-amino-5-chlorobenzophenone Schiff bases. 2-Amino-5-chlorobenzophenone is applicable to research related to bacterial infections.\n
    2-Amino-5-chlorobenzophenone
  • HY-101873
    Atorvastatin lactone 125995-03-1
    Atorvastatin lactone is a myotoxic reagent and a metabolite of Atorvastatin acid, an HMG-CoA reductase inhibitor. Atorvastatin lactone exhibits myotoxicity.
    Atorvastatin lactone
  • HY-D1005A25
    Poloxamer 403 (P123) 9003-11-6
    Poloxamer 403 P123 is a block copolymer of polyoxyethylene and polyoxypropylene with an average molecular weight of 5750. Poloxamer has the ability to inhibit P-gp. Poloxamer 403 increases creatine kinase levels. Poloxamer 403 is myotoxic.
    Poloxamer 403 (P123)
  • HY-145724
    Drisapersen 1251830-50-8
    Drisapersen (Kyndrisa) is a 2'-O-methyl phosphorothioate RNA antisense oligonucleotide that induces exon 51 skipping. Drisapersen induces skipping of exon 51 during Dystrophin pre-mRNA splicing, allowing the synthesis of partially functional Dystrophin. Drisapersen can be used in research related to Duchenne muscular dystrophy.
    Drisapersen
  • HY-177564
    Delpacibart zotadirsen 2929240-20-8
    Delpacibart zotadirsen (Del-zota), an antibody oligonucleotide conjugate (AOC), consists of a monoclonal antibody (Delpacibart) (HY-P990051) that binds to the transferrin receptor 1 (TfR1) conjugated to a phosphorodiamidate morpholino conjugate (PMO), Delpacibart zotadirsen is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. Delpacibart zotadirsen is used for the study of myotonic dystrophy type 1 (DM1).
    Delpacibart zotadirsen
  • HY-113152
    Hypogeic acid (50mg/ml in ethanol) 2416-19-5 99.1%
    Hypogeic acid is a fatty acid and endogenous metabolite, with a concentration of 50 mg/mL in ethanol. The plasma level of Hypogeic acid is negatively correlated with the prevalence of interstitial lung disease in idiopathic inflammatory myopathy. Hypogeic acid can be used in studies related to idiopathic inflammatory myopathy.
    Hypogeic acid (50mg/ml in ethanol)
  • HY-145725A
    Baliforsen 1698048-23-5 98.12%
    Baliforsen (ISIS 5987690) is an antisense oligonucleotide (ASO) that inhibits DMPK mRNA. Baliforsen binds within exon 9 of the human DMPK transcript to promote RNase H1-mediated degradation Baliforsen can be used for the research of myotonic dystrophy type 1.
    Baliforsen
  • HY-145512
    N-(α-Linolenoyl) tyrosine 259143-19-6 98.98%
    N-(α-Linolenoyl) tyrosine (NLT) is a dopaminergic agonist capable of crossing the blood-brain barrier. N-(α-Linolenoyl) tyrosine increases the level, turnover rate and release amount of dopamine in the striatum. N-(α-Linolenoyl) tyrosine modulates rotational behavior in a rat model with unilateral striatal injury and alleviates excessive blinking symptoms in models induced by dopamine-depleting agents. N-(α-Linolenoyl) tyrosine can be used for research on Parkinson's disease and idiopathic blepharospasm.
    N-(α-Linolenoyl) tyrosine
  • HY-130687A
    Psicose 23140-52-5 99.90%
    Psicose (DL-Psicose) is an orally effective sugar substitute. Psicose activates the PI3K/Akt/mTOR pathway to promote muscle synthesis. Psicose upregulates IGF-1 and downregulates Myostatin. Psicose normalizes mitochondrial dysfunction by increasing G6P activity. Psicose enhances the activity of antioxidant enzymes and reduces oxidative stress markers. Psicose increases muscle mass, grip strength and muscle weight in aged mice and diet-induced obese mice. Psicose improves obesity and type 2 diabetes. Psicose can be used in the research of age-related sarcopenia.
    Psicose
  • HY-102020A
    RG3039 hydrochloride 1466525-84-7 98.15%
    RG3039 hydrochloride is an orally active, blood-brain barrier-permeable DcpS inhibitor with an IC50 of 4.2 nM against hDcpS. RG3039 hydrochloride inhibits the decapping activity of DcpS and maintains DcpS in a catalytically inactive conformation in the central nervous system and other tissues. RG3039 hydrochloride extends survival and improves function in spinal muscular atrophy mice. RG3039 hydrochloride is applicable to research related to spinal muscular atrophy.
    RG3039 hydrochloride
  • HY-177972
    Zotadirsen
    Zotadirsen, one of the components of the AOC Delpacibart zotadirsen (HY-177564), is composed of a phosphorodiamidate morpholino oligomers (PMOs) and SMCC linker (HY-42360). Zotadirsen specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. Zotadirsen can be used to synthesize AOC drugs. Zotadirsen can also be used in the research of Duchenne muscular dystrophy (DM).
    Zotadirsen
  • HY-167983
    Cx43 HC-IN-1 1840896-10-7
    Cx43 HC-IN-1 (Compound D4) is a selective and orally active inhibitor of connexin hemichannels (Cx43 HC). Cx43 HC-IN-1 effectively inhibits the hemichannel activity mediated by Cx43/Cx45 in denervated skeletal muscle fibers, significantly increasing the reinnervation rate of muscle fibers by neurons. Cx43 HC-IN-1 reduces neuroinflammation and neuronal overexcitation by inhibiting hemichannels in glial cells in the brain, and alleviates epilepsy in mice. Cx43 HC-IN-1 can be used for research on epilepsy and muscle diseases.
    Cx43 HC-IN-1